Vitae Pharmaceuticals of Fort Washington, PA has inked a deal to collaborate with GlaxoSmithKline on developing drugs for hypertension and other cardiovascular diseases. Vitae gains an unspecified upfront payment and a deal that is worth up to $175 million for a successful development program.
"Offering significant potency and oral availability, our unique renin inhibitor compounds show promise as a breakthrough treatment for hypertension. We are very excited to work with GSK to create best-in-class medicines that make a difference and meaningfully improve patient outcomes," said Jeffrey Hatfield, CEO of Vitae.
- read this release for more